News

AstraZeneca has unveiled plans to sequence up to two million genomes in a bid to identify genetic mutations that drive disease.

The National Health Service is rolling out an evidence-based tool over the next five years that should help people with long-term conditions better manage their own health and care needs.

A pioneering new research centre will be officially launched at Exeter University this week with the aim of using predictive mathematical models to revolutionise the diagnosis and prognosis of a range of common chronic health conditions.

A National Audit Office report has concluded that the Department of Health and NHS England are starting to make headway on actions necessary to instil new access and waiting times standards for people with mental health conditions, but also stresses that “much needs to be done”.

Data from a late-stage trial testing Amgen’s Nplate in children with symptomatic immune thrombocytopenia (ITP) shows that the drug induced a durable platelet response, raising hopes for a new treatment option to help reduce bleeds in patients. 

The National Institute for Heath and Care Excellence is supporting the use of Sanofi’s prostate cancer drug Jevtana on the National Health Service following a second cost-appraisal of the drug.

US regulators have assigned GW Pharmaceuticals’ cannabidiol Epidiolex orphan drug designation for the treatment of the rare genetic disorder Tuberous Sclerosis Complex.

Who will be crowned International Clinical Researcher of the Year 2016?

PharmaTimes Media was delighted to announce the winners of this prestigious competition at a stunning awards ceremony in Atlanta, Georgia

MPs are calling on the government and heath and social care watchdogs to “urgently” link care for people with dementia and co-morbidities, as the habitual treatment of concurrent illnesses in isolation is disjointing care.

GP leaders have welcomed a multi-billion-pound transformation plan for general practice in England, which has been hailed as “the most significant piece of news” for the profession since the 1960s.

AbbVie has signed a deal potentially worth up to $685 million to develop and commercialise argenx’s ARGX-115, a preclinical-stage human antibody programme centred on the immuno-oncology target GARP. 

GlaxoSmithKline has teamed up with Sanford Burnham Prebys Medical Discovery Institute to study brain function and seek out new therapeutic targets for neurological disorders.

Novartis’ Afinitor has significantly reduced treatment-resistant seizures in patients with tuberous sclerosis complex (TSC) taking part in the Phase III EXIST-3 trial.

Three million patients began tapping into new apps, safety devices, on-line networks, and a stream of other new technologies and services during the first nine months of a pioneering programme designed to introduce new innovations to the NHS.